Our Team

Dr. Bill Elliott, PhD (Co-founder) has broad experience in cancer drug discovery and development from his work at Parke-Davis, Molecular Imaging Research, and Karmanos Cancer Institute. Bill cofounded Molecular Imaging Research, which Charles River Laboratories subsequently acquired. Bill serves as Chief Technology Officer.

Dr. Elliott brings over 40 years of scientific knowledge in various aspects in oncology gained during his pharmaceutical, drug discovery and drug development work with Parke Davis/Pfizer and ProNAi Therapeutics, and CRO experience at MIR Preclinical Services/Charles River Discovery and Imaging Services and BioDuro, a Pharmaceutical Product Development Company. Bill was a scientific co-founder of MIR, a private CRO, in 2003 with a focus on translational and molecular imaging, serving as MIR’s principal scientist for Pharmacology Services across therapeutic areas. Dr. Elliott also led all research activities at ProNAi for preclinical and clinical compounds during its early startup days before IPO. Dr Elliott has also implemented Non GLP Standard Operating Procedures and associated regulatory compliance. He will assist in Peptinovo’s analytical, lab, and regulatory efforts. On the clinical side, he spent six years as a SoCRA Credentialed Clinical Research Coordinator at Karmanos Cancer Institute and is thus familiar with clinical trial protocols and operations. Bill has numerous publications and abstracts in the drug discovery and development area. Publications can be found on his NCBI “My Bibliography” page: see here. McConville, P., Elliott, W.L., Kreger, A., Lister, R., Moody, J.B., Trachet, E., Urban, F., and Leopold, W.R. (2007). Preclinical Models of Tumor Growth and Response. In: Cancer Drug Discovery and Development: In Vivo Imaging of Cancer Therapy. A.F.Shields, and P.Price, eds. (Hummana Press: Totowa, N.J.), pp. 13-32.